Neutrophil-lymphocyte ratio is associated with prognosis in patients who underwent potentially curative resection for gastric cancer

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorSZOR, Daniel Jose
dc.contributor.authorDIAS, Andre Roncon
dc.contributor.authorPEREIRA, Marina A.
dc.contributor.authorRAMOS, Marcus F. K. P.
dc.contributor.authorZILBERSTEIN, Bruno
dc.contributor.authorCECCONELLO, Ivan
dc.contributor.authorRIBEIRO, Ulysses
dc.date.accessioned2018-09-13T15:23:44Z
dc.date.available2018-09-13T15:23:44Z
dc.date.issued2018
dc.description.abstractBackground and ObjectivesThe role of inflammation in cancer development is a well-known phenomenon that may be represented by the neutrophil-lymphocyte ratio (NLR). The present research intends to determine the impact of NLR on the survival outcome of patients with gastric cancer (GC), and to evaluate its use as a stratification factor for the staging groups. MethodsData regarding clinical characteristics, surgery, pathology, and follow-up were retrospectively collected from our single-center prospective database. Blood samples were obtained before surgery. ResultsA total of 383 patients (231 males) who underwent gastrectomy with lymphadenectomy were evaluated between 2009 and 2016. NLR established cutoff was 2.44, and patients were divided in NLR 2.44 (hNLR) and <2.44 (lNLR). hNLR patients (38.4% of the cases) had lower disease-free survival and overall survival (OS) compared to lNLR patients (P=0.047 and P=0.045, respectively). Risk stratification according to NLR value was done in same tumor depth (T4 and <T4), stage (III and <III) and lymph node status (N+ and N-) group of patients. The OS was significantly lower when NLR was high in same tumor depth (P=0.032) and stage (P=0.020), but not in same lymph node status patients (P=0.184). In a multivariate analysis, NLR was an independent factor of worse OS (HR 1.50 95%CI 1.27-4.21, P=0.048). ConclusionA high NLR was an independent risk factor for reduced survival in GC patients submitted to potentially curative resection. Calculating NLR is easily reproducible and may be incorporated in pre-operative evaluation.
dc.description.conferencedateOCT, 2017
dc.description.conferencelocalRio de Janeiro, BRAZIL
dc.description.conferencename13th Brazilian Congress of Surgical Oncology
dc.description.indexMEDLINE
dc.identifier.citationJOURNAL OF SURGICAL ONCOLOGY, v.117, n.5, Special Issue, p.851-857, 2018
dc.identifier.doi10.1002/jso.25036
dc.identifier.eissn1096-9098
dc.identifier.issn0022-4790
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/28117
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofJournal of Surgical Oncology
dc.rightsrestrictedAccess
dc.rights.holderCopyright WILEY
dc.subjectgastrectomy
dc.subjectgastric cancer
dc.subjectneutrophil-lymphocyte ratio
dc.subject.otherpredicts poor survival
dc.subject.othercell lung-cancer
dc.subject.otherpreoperative neutrophil
dc.subject.othertumor
dc.subject.othercarcinoma
dc.subject.otherinflammation
dc.subject.othermicroenvironment
dc.subject.otheradenocarcinoma
dc.subject.othermetaanalysis
dc.subject.othermetastasis
dc.subject.wosOncology
dc.subject.wosSurgery
dc.titleNeutrophil-lymphocyte ratio is associated with prognosis in patients who underwent potentially curative resection for gastric cancer
dc.typearticle
dc.type.categoryarticle; proceedings paper
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus22
hcfmusp.contributor.author-fmusphcDANIEL JOSE SZOR
hcfmusp.contributor.author-fmusphcANDRE RONCON DIAS
hcfmusp.contributor.author-fmusphcMARINA ALESSANDRA PEREIRA
hcfmusp.contributor.author-fmusphcMARCUS FERNANDO KODAMA PERTILLE RAMOS
hcfmusp.contributor.author-fmusphcBRUNO ZILBERSTEIN
hcfmusp.contributor.author-fmusphcIVAN CECCONELLO
hcfmusp.contributor.author-fmusphcULYSSES RIBEIRO JUNIOR
hcfmusp.description.beginpage851
hcfmusp.description.endpage857
hcfmusp.description.issue5
hcfmusp.description.issueSpecial Issue
hcfmusp.description.volume117
hcfmusp.origemWOS
hcfmusp.origem.pubmed29509963
hcfmusp.origem.scopus2-s2.0-85047835144
hcfmusp.origem.wosWOS:000434145500005
hcfmusp.publisher.cityHOBOKEN
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceAggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029
hcfmusp.relation.referenceAzab B, 2012, ANN SURG ONCOL, V19, P217, DOI 10.1245/s10434-011-1814-0
hcfmusp.relation.referenceBalkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
hcfmusp.relation.referenceBOBB GA, 1967, TOXICOL APPL PHARM, V11, P558, DOI 10.1016/0041-008X(67)90056-7
hcfmusp.relation.referenceChasseuil E, 2017, ACTA DERM VENEREOL, DOI 10. 2340/00015555-2872
hcfmusp.relation.referenceClarke SJ, 2011, CLIN PHARMACOL THER, V90, P475, DOI 10.1038/clpt.2011.122
hcfmusp.relation.referenceGondo T, 2012, UROLOGY, V79, P1085, DOI 10.1016/j.urology.2011.11.070
hcfmusp.relation.referenceGraziosi L, 2015, AM J SURG, V209, P333, DOI 10.1016/j.amjsurg.2014.06.014
hcfmusp.relation.referenceHirashima M, 1998, J CANCER RES CLIN, V124, P329, DOI 10.1007/s004320050178
hcfmusp.relation.referenceHuang Y, 2017, ONCOTARGETS THER, V10, P1165, DOI 10.2147/OTT.S126637
hcfmusp.relation.referenceJapanese Gastric Cancer Association, 1998, GASTRIC CANCER, V1, P10, DOI 10.1007/S101209800016]
hcfmusp.relation.referenceJiang N, 2014, BIOMARKERS, V19, P444, DOI 10.3109/1354750X.2014.926567
hcfmusp.relation.referenceJung MR, 2011, J SURG ONCOL, V104, P504, DOI 10.1002/jso.21986
hcfmusp.relation.referenceKhoja L, 2016, CANCER MED-US, V5, P2792, DOI 10.1002/cam4.878
hcfmusp.relation.referenceLiang W, 2016, CANCER IMMUNOL RES, V4, P83, DOI 10.1158/2326-6066.CIR-15-0313
hcfmusp.relation.referenceLiu CL, 2013, J SURG ONCOL, V107, P493, DOI 10.1002/jso.23270
hcfmusp.relation.referenceLIU YK, 1978, CANCER, V41, P1193, DOI 10.1002/1097-0142(197803)41:3<1193::AID-CNCR2820410358>3.0.CO;2-Z
hcfmusp.relation.referenceMotomura T, 2013, J HEPATOL, V58, P58, DOI 10.1016/j.jhep.2012.08.017
hcfmusp.relation.referenceNAKAHARA K, 1987, J SURG ONCOL, V36, P155, DOI 10.1002/jso.2930360302
hcfmusp.relation.referenceNakajima K, 1998, TUMOR BIOL, V19, P464, DOI 10.1159/000030038
hcfmusp.relation.referenceOpdenakker G, 2004, INT J DEV BIOL, V48, P519, DOI 10.1387/ijdb.041796go
hcfmusp.relation.referenceParamanathan A, 2014, SURG ONCOL, V23, P31, DOI 10.1016/j.suronc.2013.12.001
hcfmusp.relation.referencePasini FS, 2014, J GASTROENTEROL, V49, P1453, DOI 10.1007/s00535-013-0904-0
hcfmusp.relation.referencePeinado H, 2008, CANCER CELL, V14, P347, DOI 10.1016/j.ccr.2008.10.012
hcfmusp.relation.referenceRashid F, 2010, WORLD J SURG ONCOL, V8, DOI 10.1186/1477-7819-8-1
hcfmusp.relation.referenceRobert ME, 2008, HUM PATHOL, V39, P9, DOI 10.1016/j.humpath.2007.05.024
hcfmusp.relation.referenceRUSSELL SW, 1976, INT J CANCER, V18, P322, DOI 10.1002/ijc.2910180309
hcfmusp.relation.referenceSarraf KM, 2009, J THORAC CARDIOV SUR, V137, P425, DOI 10.1016/j.jtcvs.2008.05.046
hcfmusp.relation.referenceShimada H, 2010, GASTRIC CANCER, V13, P170, DOI 10.1007/s10120-010-0554-3
hcfmusp.relation.referenceSpeiser DE, 2016, NAT REV IMMUNOL, V16, P500, DOI 10.1038/nri.2016.80
hcfmusp.relation.referenceStotz M, 2013, BRIT J CANCER, V109, P416, DOI 10.1038/bjc.2013.332
hcfmusp.relation.referenceSun JX, 2016, DIS MARKERS, P1, DOI 10.1155/2016/7862469
hcfmusp.relation.referenceTABUCHI T, 1992, ANTICANCER RES, V12, P795
hcfmusp.relation.referenceTempleton AJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju124
hcfmusp.relation.referenceTunes-da-Silva G, 2011, COMPUT STAT DATA AN, V55, P226, DOI 10.1016/j.csda.2010.02.016
hcfmusp.relation.referenceWalczak H, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008698
hcfmusp.relation.referenceWalsh Sr, 2005, J SURG ONCOL, V91, P181, DOI 10.1002/jso.20329
hcfmusp.relation.referenceWang SC, 2016, ANN SURG, V263, P292, DOI 10.1097/SLA.0000000000001189
hcfmusp.relation.referenceXue TC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096072
hcfmusp.relation.referenceYamanaka T, 2007, ONCOLOGY-BASEL, V73, P215, DOI 10.1159/000127412
hcfmusp.relation.referenceZhang X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111906
hcfmusp.relation.referenceZhang XJ, 2015, INT J SURG, V21, P84, DOI 10.1016/j.ijsu.2015.07.681
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublicationa954f618-858f-4bd6-9107-d9348c476513
relation.isAuthorOfPublicationff47b46c-9a86-4895-aa70-8d6b7d61856d
relation.isAuthorOfPublicationb970c5a9-d9a1-4c42-940b-aa94a5730f5f
relation.isAuthorOfPublication3696099c-2c5f-4ab8-a657-097ee4046081
relation.isAuthorOfPublicationc51ddcd6-978f-4957-b9c5-62ed87b620bf
relation.isAuthorOfPublicatione0a211ed-1f62-4700-bf7b-a7cd39218361
relation.isAuthorOfPublicationa4bfdcf9-89f7-472f-9936-aa817156faad
relation.isAuthorOfPublication.latestForDiscoverya954f618-858f-4bd6-9107-d9348c476513
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_SZOR_Neutrophillymphocyte_ratio_is_associated_with_prognosis_in_patients_2018.PDF
Tamanho:
685.25 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/35
Artigos e Materiais de Revistas Científicas - LIM/37
Artigos e Materiais de Revistas Científicas - LIM/38
Carregar mais